ViewRay, Inc. (VRAY)
(Delayed Data from NSDQ)
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
5 Top Momentum Stocks of June Amid Resurgence of Coronavirus
by Nalak Das
Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.
Top Ranked Momentum Stocks to Buy for June 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 23rd
Tandem Diabetes (TNDM) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Tandem Diabetes (TNDM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.
ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 0.00% and 14.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
IDEXX (IDXX) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
IDEXX Laboratories (IDXX) companion animal clinical visits decrease due to the impact of the coronavirus pandemic.
QIAGEN (QGEN) Q1 Earnings to Gain on Growing Test Kit Sales
by Zacks Equity Research
QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.
Align Technology (ALGN) Q1 Earnings Miss, Margins Down
by Zacks Equity Research
Align Technology's (ALGN) Scanner and Services reports COVID-19-led lower sales in North America and APAC region.
LabCorp's (LH) Q1 Earnings Beat Estimates, Margins Down
by Urmimala Biswas
LabCorp's (LH) Covance Drug Development revenues improve despite COVID-19 hurdles.
Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline
by Zacks Equity Research
The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.
Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.
Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Professional and Managed services units, and international revenue growth.
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) first-quarter earnings benefit from solid segmental performance.
Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.
Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Masimo (MASI) sees solid growth in key Product segment in Q1.
Ecolab (ECL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Strength in the Global Industrial and Institutional segments drives Ecolab's (ECL) first-quarter results.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.
Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View
by Zacks Equity Research
Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.
ViewRay (VRAY) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.
Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow
by Zacks Equity Research
On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.
Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results
by Nalak Das
Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.
Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance
by Zacks Equity Research
Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.
ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -24.00% and -3.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?